Evangelos S. Gragoudas, M.D.

Director, Retina Service

Specialties

Retina

Ophthalmic Oncology

Macular Degeneration

Board Certification

  • Ophthalmology

Main Campus
243 Charles Street
Boston, MA 02114
Phone: 617-573-3515
Fax: 617-573-3678

Overview

Biography

Dr. Gragoudas is presently the Charles Edward Whitten Professor of Ophthalmology at the Harvard Medical School and Director of the Retina Service at Mass Eye and Ear Infirmary.  A prolific clinician-scientist, Dr. Gragoudas has published over 250 articles in peer-reviewed journals and written or authored more than 100 chapters, reviews, and books.  Dr. Gragoudas is considered a world authority on the diagnosis and management of intraocular tumors.  He pioneered the use of proton therapy in eye tumors, a treatment modality that has been proven to be extremely successful and has been used in many ocular oncology centers around the world.

Dr. Gragoudas’ second major contribution to Ophthalmology is the use of photodynamic therapy (PDT) for the treatment of AMD.  He collaborated with Dr. Joan W. Miller on preclinical studies of PDT and based on large clinical trials, photodynamic therapy became the first widely used treatment for neovascular AMD.

Dr. Gragoudas’ third major contribution to Ophthalmology has been his work on ocular angiogenesis and anti-angiogenesis therapy.  He worked with a group of ophthalmologists, including Drs. Joan Miller, Tony Adamis, Pat D’Amore and others to demonstrate the critical role of vascular endothelial growth factor (VEGF) in ocular neovascularization and went on to develop therapies targeting VEGF.  In 2014 Dr. Gragoudas and his colleagues received the Champalimaud Vision Award for their work on using anti-angiogenesis drug therapy for the treatment of age-related macular degeneration.  This award is considered the “Nobel Prize” in Vision Research.

He has received numerous honors and awards including: Academy Honor Award of American Academy of Ophthalmology; Retina Research Foundation prize of the Jules Gonin Lectureship; Research to Prevent Blindness Senior Scientific Investigators Award; Senior Achievement Award of American Academy of Ophthalmology; J. Donald M.Gass Medal of the Macula Society; the Arnall Patz Medal of the Macula Society; Mildred Weisenfeld Award for Excelence in Ophthalmology from ARVO.

Clinical Interests

Retinal diseases, macular degeneration, intraocular tumors

Research Interests

Retinal diseases, macular degeneration, intraocular tumors

Publications

For a full publication list, please see his CV.

Proton irradiation for peripapillary and parapapillary melanomas. Lane AM, Kim IK, Gragoudas ES. Arch Ophthalmol. 2011 Sep;129(9):1127-30.

Evaluation of tissue interactions with mechanical elements of a transscleral drug delivery device. Cohen SJ, Chan RVP, Keegan M, Andreoli CM, Borenstein JT, Miller JW, Gragoudas ES. Pharmaceutics. 2012 Mar 12;4(1):212-229.

High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Daniels AB, Lee JE, MacConaill LE, Pabescandolo E, Hummelen PV, Adams SM, DeAngelis MM, Hahn WC, Gragoudas ES, Harbour W, Garraway LA, Kim IK. Invest. Ophthalmol. Vis. Sci. 2012 Oct 9;53(11): 6991-6996.

Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. Njauw CNJ, Kim I, Piris A, Gabree M, Taylor M, Lane AM, DeAngelis MM, Gragoudas E, Duncan LM, Tsao H. PLOS One. 2012;7(4):e35295.

Aminoimidazole carboxamide ribonucleotide (AICAR) inhibits the growth of retinoblastoma in vivo by decreasing angiogenesis and inducing apoptosis. Theodoropoulou S, Brodowska K, Kayama M, Morizane Y, Miller JW, Gragoudas ES, Vavvas DG. PLoS One. 2013;8(1):e52852.

View a complete list of publications on pubmed.gov>>

Education

Education

  • Athens National & Kapodistrian University, Athens, Greece, M.D.

Residency

  • Ophthalmology, Boston University, Boston Medical Center

Fellowship

  • Vitreoretinal Surgery, Mass. Eye and Ear